ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Brings back memories

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Apr 25, 2023 4:19pm

93 Views

Post# 35413246

RE:RE:Brings back memories

Summary from dr. Cashman preaentation

Summary

• ProMIS monoclonal antibodies selective for misfolded RACK1 (RACK1mis mAb) showed coaggregation of RACK1 and TDP-43 in ALS and FTLD-TDP, and in cell culture;

• RACK1 knockdown alleviated TDP-43 aggregation as well as associated global translational suppression in cultured cells;

• RACK1 knockdown was well-tolerated in cultured cells in vitro and D. melanogaster neurons in vivo;

• RACK1 knockdown ameliorated retinal and motor neuron neurodegeneration in D. melanogaster in vivo;

• These findings support RACK1 knockdown as a potential therapeutic approach for TDP-43 proteinopathy in non-SOD1

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali